Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cell Therapeutics Should Consider Different Trial Design For Pixuvri, FDA's Pazdur Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The odds were against Cell Therapeutics from the beginning of the Oncology Drugs Advisory Committee meeting, as FDA officials had concluded that the single, incomplete clinical trial did not provide enough evidence of efficacy.

You may also be interested in...



CTI’s Pixuvri Flops Again At British NICE, As Discount Fails To Impress

Despite a sizeable price cut, uncertainty surrounding CTI’s non-Hodgkin’s lymphoma therapy Pixuvri has landed it with a second NICE rejection.

CTI Finds Pixuvri’s Conditional Authorization Is Not Enough To Win NICE Approval

In an early stage decision, NICE rejects Pixuvri for multiply relapsed or refractory aggressive non-Hodgkin's lymphoma, citing lack of evidence and cost-effectiveness.

Saving Face? Cell Therapeutics Withdraws Pixantrone NDA Ahead Of Advisory Committee Review

Company’s announcement that it pulled the NDA for its investigational non-Hodgkin’s lymphoma treatment comes after the sponsor would have received FDA’s background briefing document for the Feb. 9 Oncologic Drugs Advisory Committee meeting.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel